Comparison · NCT00318474-sae
Mycophenolate Mofetil (MMF) vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Mycophenolate Mofetil (MMF) vs Placebo: serious adverse events. Trial comparisons, record NCT00318474-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00318474-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.04 | 0.0071 | 0.195 | wilson | |
| Risk in group 2 | 0.037 | 0.00657 | 0.183 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00296 | -0.147 | 0.161 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.0713 | 16.4 | log | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.0641 | 18.3 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Mycophenolate Mofetil (MMF) than on Placebo | 337 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Mycophenolate Mofetil (MMF) | Subjects receive ACEi, FOS, and MMF. Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.~Mycophenolate Mofetil (MMF) | 1 | 25 | EG000 |
| Group 2 | Placebo | Subjects receive ACEi and FOS and placebo. | 1 | 27 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- The trial design is 13 visits over 27 months.
Source ClinicalTrials.gov
Trial
- Title
- Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy
- NCT number
- NCT00318474
- Phases
- PHASE3
- Conditions
- IgA Nephropathy
- Interventions
- Mycophenolate Mofetil (MMF), MMF Placebo, ACEi, FOS
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Results first posted
- 2014-10-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00318474?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00318474-sae